← Leaderboards
Pan Li
Johns Hopkins University
$4,694,846
Attributed
$4,947,750
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,947,750 · 5
By mechanism
R01$3,526,368 · 2
R21$1,421,382 · 3
Top collaborators
- Lisa M. Ellerby1 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Akira Sawa$22,088,823
- Koko Ishizuka$2,307,957
- Elizabeth Nesoff$3,192,732
- Xiaoqin Wang$34,711,962
- Christopher A Ross$35,771,871
Others in their field
Other Emerging Leaders on “Proteins”
- John Damon Chodera · Sloan-Kettering Inst Can Research$50,971,767
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Susan M Landau · University Of California Berkeley$47,252,026
- Timothy Fouts · Advanced Bioscience Laboratories, Inc.$40,723,314
- Chris Karlovich · Leidos Biomedical Research, Inc.$38,534,220
- Mathangi Thiagarajan · Leidos Biomedical Research, Inc.$37,695,154
Research focus
ProteinsLengthNeurodegenerative DisordersGenesCellsInduced Pluripotent Stem CellPathway InteractionsBrainPathogenesisMutationOverexpressionExperimental StudyHuntington DiseaseNeurotoxicityClustered Regularly Interspaced Short Palindromic RepeatsRna SplicingToxic EffectCag RepeatHomologous RecombinationN-TerminalVariantGenerationsNeuronsFuture
Grant awards (10)
Functional characterization of schizophrenia rare variants using genetically engineered human iPSCs$699,992
R01 · FY2025 · MH · contact PI
Molecular Pathogenesis of spinocerebellar ataxia type 12$437,343
R01 · FY2025 · NS · contact PI
Functional characterization of schizophrenia rare variants using genetically engineered human iPSCs$703,284
R01 · FY2024 · MH · contact PI
Molecular Pathogenesis of spinocerebellar ataxia type 12$474,498
R01 · FY2024 · NS · contact PI
Brain-targeted delivery of therapeutic molecules by exosomes derived from engineered human iPS cells: a potential therapeutic approach for Huntington's disease$204,302
R21 · FY2024 · NS · contact PI
Functional characterization of schizophrenia rare variants using genetically engineered human iPSCs$696,676
R01 · FY2023 · MH · contact PI
Molecular Pathogenesis of spinocerebellar ataxia type 12$514,575
R01 · FY2023 · NS · contact PI
Brain-targeted delivery of therapeutic molecules by exosomes derived from engineered human iPS cells: a potential therapeutic approach for Huntington's disease$260,959
R21 · FY2023 · NS · contact PI
Novel knock-in mouse models of spinocerebellar ataxia type 12$450,313
R21 · FY2020 · NS · contact PI
Evaluation of the role of RNA toxicity in SCA2 pathogenesis using genome editing in patient iPSCs$505,808
R21 · FY2019 · NS · contact PI